Ginsberg Lionel, Malik Omar, Kenton Anthony R, Sharp David, Muddle John R, Davis Mary B, Winer John B, Orrell Richard W, King Rosalind H M
University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, and Department of Neurology, Royal Free Hospital,UK.
Brain. 2004 Jan;127(Pt 1):193-202. doi: 10.1093/brain/awh017. Epub 2003 Nov 7.
Classically, the course of Charcot-Marie-Tooth (CMT) disease is gradually progressive. We describe eight atypical patients who developed acute or subacute deterioration. Seven of these had genetically proven CMT disease type 1A (CMT1A) due to chromosome 17p11.2-12 duplication, and one had X-linked disease (CMTX) due to a mutation in the GJB1 gene. In this group there was sufficient clinical, electrophysiological and neuropathological information to indicate a diagnosis of a superimposed inflammatory polyneuropathy. The age range of the patients was 18-69 years, with a mean of 39 years. A family history of a similar neuropathic condition was present in only four patients. All eight had an acute or subacute deterioration following a long asymptomatic or stable period. Seven had neuropathic pain or prominent positive sensory symptoms. Nerve biopsy demonstrated excess lymphocytic infiltration in all eight patients. Five patients were treated with steroids and/or intravenous immunoglobulin, with variable positive response; three patients received no immunomodulatory treatment. Inflammatory neuropathy has previously been recognized in patients with hereditary neuropathy, with uncharacterized genetic defects and with CMT1B. We present detailed assessments of patients with CMT1A and CMTX, including nerve biopsy, and conclude that coexistent inflammatory neuropathy is not genotype-specific in hereditary motor and sensory neuropathy. Although this was not a formal epidemiological study, estimates of the prevalence of CMT disease and chronic inflammatory demyelinating polyneuropathy indicate that the association is more frequent than would be expected by chance. This has implications for understanding the pathogenesis of inflammatory neuropathies and raises important considerations in the management of patients with hereditary neuropathies. If a patient with CMT disease experiences an acute or subacute deterioration in clinical condition, treatment of a coexistent inflammatory neuropathy with steroids or immunoglobulin should be considered.
典型的夏科-马里-图思(CMT)病病程呈逐渐进展。我们描述了8例出现急性或亚急性病情恶化的非典型患者。其中7例经基因检测证实为17号染色体p11.2-12区域重复所致的1A型CMT病(CMT1A),1例因GJB1基因突变患有X连锁疾病(CMTX)。该组患者具备足够的临床、电生理和神经病理学信息,提示诊断为叠加性炎性多发性神经病。患者年龄范围为18至69岁,平均39岁。仅有4例患者有类似神经病变的家族史。所有8例患者在长期无症状或病情稳定后均出现急性或亚急性病情恶化。7例有神经病理性疼痛或明显的感觉异常阳性症状。神经活检显示所有8例患者均有淋巴细胞浸润增多。5例患者接受了类固醇和/或静脉注射免疫球蛋白治疗,反应不一;3例患者未接受免疫调节治疗。此前在患有遗传性神经病、基因缺陷未明确的患者以及CMT1B患者中已认识到炎性神经病。我们对CMT1A和CMTX患者进行了详细评估,包括神经活检,并得出结论,遗传性运动和感觉神经病中共存的炎性神经病并非基因型特异性。尽管这并非一项正式的流行病学研究,但对CMT病和慢性炎性脱髓鞘性多发性神经病患病率的估计表明,这种关联比偶然预期的更为常见。这对于理解炎性神经病的发病机制具有重要意义,并在遗传性神经病患者的管理中提出了重要的考虑因素。如果CMT病患者临床病情出现急性或亚急性恶化,应考虑使用类固醇或免疫球蛋白治疗共存的炎性神经病。